Literature DB >> 1308935

[The evolution of chronic chagasic cardiopathy. I. The influence of parasitemia].

J B Pereira1, H P Wilcox, J R Coura.   

Abstract

During eight years (1982-1990) the evolution of chronic chagasic cardiopathy and its relation to parasitemia was evaluated in 279 patients, 85 men and 194 women, studied by resting electrocardiography and xenodiagnosis. All patients were residents in Virgem da Lapa, State of Minas Gerais, Brazil and their ages varied from 7 to 76 years (average 42.6 y). According to the results of the electrocardiograms the evolution of chagasic cardiopathy was classified as a) unchanged--when there was no change of the initial pattern off the ECG, b) progressive--when there was deterioration of the ECG pattern and c) regressive-when there was normalization or regression of the ECG alterations. Regarding xenodiagnosis 120 were considered with positive parasitemia, one or more xenodiagnoses positive, and 159 with negative parasitemia--all xenodiagnoses negative. The results showed: a) chagasic cardiopathy unchanged in 172 (61.6%) patients, b) progressive in 99 (35.5%) patients and c) regressive in 8 (2.9%). There was no relation between the evolution of chagasic cardiopathy and parasitemia. Independent from parasitemia, the cardiopathy was progressive according to the age of the patients and significantly greater in males. In conclusion we can state that evolution of chronic chagasic cardiopathy is associated with the age and with the male sex, but not with parasitemia, and this may suggest that parasitemia is not related to the development of the chronic chagasic cardiopathy.

Entities:  

Mesh:

Year:  1992        PMID: 1308935     DOI: 10.1590/s0037-86821992000200003

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  14 in total

1.  Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain reaction.

Authors:  A L Basquiera; A Sembaj; A M Aguerri; M Omelianiuk; S Guzmán; J Moreno Barral; T F Caeiro; R J Madoery; O A Salomone
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

Review 2.  The role of infections in autoimmune disease.

Authors:  A M Ercolini; S D Miller
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

3.  Chagas cardiomyopathy in the context of the chronic disease transition.

Authors:  Alicia I Hidron; Robert H Gilman; Juan Justiniano; Anna J Blackstock; Carlos Lafuente; Walter Selum; Martiza Calderon; Manuela Verastegui; Lisbeth Ferrufino; Eduardo Valencia; Jeffrey A Tornheim; Seth O'Neal; Robert Comer; Gerson Galdos-Cardenas; Caryn Bern
Journal:  PLoS Negl Trop Dis       Date:  2010-05-18

4.  Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors.

Authors:  Ester C Sabino; Antonio L Ribeiro; Vera M C Salemi; Claudia Di Lorenzo Oliveira; Andre P Antunes; Marcia M Menezes; Barbara M Ianni; Luciano Nastari; Fabio Fernandes; Giuseppina M Patavino; Vandana Sachdev; Ligia Capuani; Cesar de Almeida-Neto; Danielle M Carrick; David Wright; Katherine Kavounis; Thelma T Goncalez; Anna Barbara Carneiro-Proietti; Brian Custer; Michael P Busch; Edward L Murphy
Journal:  Circulation       Date:  2013-02-07       Impact factor: 29.690

5.  Familial analysis of seropositivity to Trypanosoma cruzi and of clinical forms of Chagas disease.

Authors:  Roseane L Silva-Grecco; Marly A S Balarin; Dalmo Correia; Aluízio Prata; Virmondes Rodrigues
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

6.  Administration of artinm lectin reduces the severity of the acute phase infection with Trypanosoma cruzi.

Authors:  Camila Botelho Miguel; Thiago Aparecido da Silva; Wellington Francisco Rodrigues; Patrícia Kellen Martins Oliveira-Brito; Maria Cristina Roque-Barreira; Javier Emílio Lazo-Chica
Journal:  FASEB Bioadv       Date:  2021-01-25

7.  Trypanosoma cruzi burden, genotypes, and clinical evaluation of Chilean patients with chronic Chagas cardiopathy.

Authors:  Werner Apt; Arturo Arribada; Inés Zulantay; Miguel Saavedra; Eduardo Araya; Aldo Solari; Sylvia Ortiz; Katherine Arriagada; Jorge Rodríguez
Journal:  Parasitol Res       Date:  2015-05-03       Impact factor: 2.289

8.  Molecular Diagnosis of Chagas Disease in Colombia: Parasitic Loads and Discrete Typing Units in Patients from Acute and Chronic Phases.

Authors:  Carolina Hernández; Zulma Cucunubá; Carolina Flórez; Mario Olivera; Carlos Valencia; Pilar Zambrano; Cielo León; Juan David Ramírez
Journal:  PLoS Negl Trop Dis       Date:  2016-09-20

9.  The role of interleukin 17-mediated immune response in Chagas disease: High level is correlated with better left ventricular function.

Authors:  Giovane R Sousa; Juliana A S Gomes; Marcos Paulo S Damasio; Maria Carmo P Nunes; Henrique S Costa; Nayara I Medeiros; Rafaelle C G Fares; Ana Thereza Chaves; Rodrigo Corrêa-Oliveira; Manoel Otávio C Rocha
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

10.  Analytical Validation of Quantitative Real-Time PCR Methods for Quantification of Trypanosoma cruzi DNA in Blood Samples from Chagas Disease Patients.

Authors:  Juan Carlos Ramírez; Carolina Inés Cura; Otacilio da Cruz Moreira; Eliane Lages-Silva; Natalia Juiz; Elsa Velázquez; Juan David Ramírez; Anahí Alberti; Paula Pavia; María Delmans Flores-Chávez; Arturo Muñoz-Calderón; Deyanira Pérez-Morales; José Santalla; Paulo Marcos da Matta Guedes; Julie Peneau; Paula Marcet; Carlos Padilla; David Cruz-Robles; Edward Valencia; Gladys Elena Crisante; Gonzalo Greif; Inés Zulantay; Jaime Alfredo Costales; Miriam Alvarez-Martínez; Norma Edith Martínez; Rodrigo Villarroel; Sandro Villarroel; Zunilda Sánchez; Margarita Bisio; Rudy Parrado; Lúcia Maria da Cunha Galvão; Antonia Cláudia Jácome da Câmara; Bertha Espinoza; Belkisyole Alarcón de Noya; Concepción Puerta; Adelina Riarte; Patricio Diosque; Sergio Sosa-Estani; Felipe Guhl; Isabela Ribeiro; Christine Aznar; Constança Britto; Zaida Estela Yadón; Alejandro G Schijman
Journal:  J Mol Diagn       Date:  2015-09       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.